Stocktoria
Lineage Cell Therapeutics, Inc. LCTX
Lineage Cell Therapeutics, Inc. (LCTX) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $14.6M at a -436.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.424 |
| Retained earnings / assets | -4.148 |
| EBIT / assets | -0.325 |
| Equity / liabilities | 0.643 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LCTX | Lineage Cell Therapeutics, Inc. | 3/9 | -12.25 | — | — |
| RLAY | Relay Therapeutics, Inc. | 3/9 | 2.96 | — | +53.4% |
| PTHS | Pelthos Therapeutics Inc. | 4/9 | -1.47 | — | — |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
| CRBU | Caribou Biosciences, Inc. | 2/9 | -9.88 | — | — |
| ACOG | Alpha Cognition Inc. | 2/9 | 3.69 | — | — |
| LENZ | LENZ Therapeutics, Inc. | 2/9 | 15.45 | — | — |
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
FAQ
Is LCTX financially healthy?
Lineage Cell Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does LCTX pay a dividend?
No, Lineage Cell Therapeutics, Inc. does not currently pay a dividend.
How profitable is LCTX?
In FY2025, Lineage Cell Therapeutics, Inc. had a net margin of -436.5% and a return on equity of -142.6%.
What is the analyst price target for LCTX?
The average Wall-Street price target for Lineage Cell Therapeutics, Inc. is $5.50, about 400.0% above the recent price, from 6 analysts.
Is LCTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Lineage Cell Therapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.